Satellos presents interim SAT-3247 data at MDA Conference

Satellos (MSLE) Bioscience announced interim clinical and biomarker data for SAT-3247 at the Muscular Dystrophy Association, MDA, Clinical & Scientific Conference in Orlando, Florida. The data include interim observations from the ongoing Phase 2 TRAILHEAD study in adults with DMD serum proteomic analysis from the previously completed 28-day, CL-101 Phase 1a/b trial, and the development of a novel muscle regeneration assessment tool. The Company also presented preclinical findings demonstrating enhanced muscle strength in a mouse model of FSHD. Interim observations from the ongoing Phase 2 TRAILHEAD study include: Continued increase in handgrip strength compared to CL-101 baseline; Overall stability in elbow and shoulder strength at Day 56 following re-enrollment; Greater improvement in strength observed among participants with greater baseline muscle mass; Additional clinical outcome assessments ongoing